2 results
Approved WMORecruiting
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
Approved WMORecruiting
The objective of this study is to assess the safety and effectiveness of the WISE System (providing LV pacing) when used in conjunction with a co-implanted system (ICD, pacemaker, CRT-P, or CRT-D) for bi-ventricular (BiV) pacing for CRT in heart…